Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide...

Area of Science:

• Oncology
• Nuclear Medicine
• Biomarker Research

Background:

• Peptide receptor radionuclide therapy (PRRT) is a key treatment for neuroendocrine tumors (NETs).
• A significant number of NET patients experience short progression-free intervals after PRRT.
• Effective biomarkers to predict treatment response and survival in NET patients undergoing PRRT are lacking.

Purpose of the Study:

• To determine the prognostic significance of various biomarkers on the survival of patients with NETs receiving initial PRRT.
• To identify potential predictors of disease progression in NET patients treated with PRRT.

Main Methods:

• Retrospective analysis of 51 NET patients treated with PRRT.
• Evaluation of hematological, inflammatory, and biochemical markers, along with clinical characteristics.
• Comparison of clinical data between patients with disease progression and those without progression.

Main Results:

• Tumor functionality emerged as the most powerful independent prognostic factor for disease progression.
• Elevated C-reactive protein (CRP) and alanine aminotransferase (ALT) were identified as independent risk factors for disease progression.
• Patients with functional tumors had significantly shorter progression-free survival (PFS) and overall survival (OS) compared to non-functional tumors.

Conclusions:

• Tumor functionality and specific biomarkers (CRP, ALT) can serve as prognostic indicators for NET patients undergoing PRRT.
• These findings may aid in identifying patients at higher risk of disease progression.
• The results support tailoring treatment strategies based on identified prognostic factors for improved patient outcomes.